Vor Biopharma Inc. Common Stock (VOR)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, at the close on 2026-10-13, Vor traded at $19.06 with a $1.1 billion market cap. This is a clinical-stage biotech: the SEC filings show no revenue in fiscal Q1 2026 (quarter ended 2026-03-31), fiscal Q2 2026 (quarter ended 2026-06-30), FY2025, FY2024, or FY2023. The losses are large: net income was -$219.6 million in fiscal Q1 2026, -$62.8 million in fiscal Q2 2026, -$696.0 million in FY2025, -$116.9 million in FY2024, and -$117.9 million in FY2023. Diluted EPS in those periods was -$5.11, -$1.16, -$70.50, -$34.03, and -$1.75. Earlier quarters show even bigger losses: fiscal Q3 2025 net income -$812.7 million and fiscal Q2 2025 net income -$1.6 billion. Free cash flow is negative at -$140.8 million trailing, a -12.5% FCF yield, and FairStock's ROCE is -21.37%. The Piotroski F-Score is 0/9 and Altman Z-Score is -2.06, both signs of acute financial weakness. The FairStock P/E of 0.11 is not meaningful against these losses, and P/B, ROE, and D/E are unavailable. The business has no demonstrated moat in the numbers. Its main asset is telitacicept, licensed from RemeGen, targeting several autoimmune diseases. That may be valuable if approved, but today it is a promise, not an earning asset. The FairStock Score is 34/100 and the Lynch category is none because of four straight unprofitable years. I would demand a very large margin of safety, and I see none in current figures.

In plain English: Vor Biopharma is a drug company that is still testing its main medicine, telitacicept, for autoimmune diseases such as myasthenia gravis, lupus, and rheumatoid arthritis. The business looks weak on current numbers: it has no reported sales in the periods shown, has lost money for years, and burns cash. At the 2026-10-13 closing price of $19.06 and a $1.1 billion market value, the price is not supported by current sales or profits; it depends mostly on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer